• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Why uniQure (QURE) Is Up 6.4% After FDA Alignment On Accelerated AMT-130 Approval Path

    Simply Wall St·08/09/2026 19:28:07
    Listen to the news
    • In the past quarter, uniQure N.V. reported slightly higher revenue of US$5.84 million but a wider net loss of US$81.06 million, and it filed a US$12.831 million shelf registration for 350,000 ordinary shares tied to its employee share plan.
    • Alongside these results, uniQure secured FDA alignment for an accelerated approval Biologics License Application for AMT-130 in Huntington’s disease, backed by a recent US$259 million capital raise intended to support the confirmatory trial and potential commercialization.
    • We’ll now examine how FDA alignment on accelerated approval for AMT-130 reshapes uniQure’s investment narrative and perceived risk profile.

    The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    uniQure Investment Narrative Recap

    To own uniQure, you need to believe that AMT-130 can become a first of its kind gene therapy for Huntington’s disease while the company manages heavy losses and dilution. The FDA alignment on an accelerated approval BLA now looks like the key near term catalyst, with trial execution and regulatory review risk still front and center. The latest quarter’s wider net loss and small revenue base mainly reinforce, rather than change, that risk profile.

    The most relevant recent announcement here is the FDA’s agreement to an accelerated approval filing for AMT-130 using 3 year data, paired with a standard of care controlled confirmatory study. This framework gives clearer sightlines on what uniQure must deliver next, but it also locks in a substantial, multi year commitment of capital and operational focus. Against that backdrop, the US$259 million raise and fresh losses highlight how dependent the story is on AMT-130 progressing as planned.

    Yet behind the accelerated approval opportunity, investors should be aware of how rising losses and future trial costs could still...

    Read the full narrative on uniQure (it's free!)

    uniQure's narrative projects $378.0 million revenue and $71.5 million earnings by 2029. This requires 175.4% yearly revenue growth and a $280.4 million earnings increase from -$208.9 million today.

    Uncover how uniQure's forecasts yield a $64.47 fair value, a 39% upside to its current price.

    Exploring Other Perspectives

    QURE 1-Year Stock Price Chart
    QURE 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already assuming only about US$112.2 million of revenue and US$19.1 million of earnings by 2029, which is a far more cautious view than the baseline narrative, and the latest FDA and funding news could push their expectations in either direction.

    Explore 5 other fair value estimates on uniQure - why the stock might be worth 22% less than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Contemplating Other Strategies?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    • Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
    • We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
    • Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.